OMEPRAZOLE TREATMENT DOES NOT AFFECT THE METABOLISM OF CAFFEINE

被引:46
作者
ANDERSSON, T
BERGSTRAND, R
CEDERBERG, C
ERIKSSON, S
LAGERSTROM, PO
SKANBERG, I
机构
[1] Research Laboratories, AB Hässle, Mölndal
关键词
D O I
10.1016/0016-5085(91)90719-2
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
This study was performed to investigate the possible influence of repeated omeprazole dosing on the metabolism of caffeine, which has been shown to reflect the activity of one specific enzyme within the hepatic cytochrome P450 family, P450IA2. Ten healthy, nonsmoking young men participated in this placebo-controlled double-blind trial. Each subject was given omeprazole, 20 mg, every morning for 1 week and placebo every morning for 1 week in random order and separated by a 2-3-week washout period. On the sixth and seventh days of each period urine was collected twice daily, and urinary metabolites of caffeine were determined by high-performance liquid chromatography. The urinary metabolite ratio of three paraxanthine 7-demethylation products relative to a paraxanthine-hydroxylation product corresponds to caffeine clearance and, therefore, to P450IA2 activity. This calculated ratio was 4.8 (95% confidence interval, 3.9-5.6) in the placebo and 4.6 (95% confidence interval, 3.6-5.5) in the omeprazole period. These results show that the metabolism of caffeine was unaltered following omeprazole treatment, indicating that omeprazole treatment has no influence on cytochrome P450IA2 activity in the clinical situation. © 1991.
引用
收藏
页码:943 / 947
页数:5
相关论文
共 42 条
[1]   A STUDY OF THE INTERACTION BETWEEN OMEPRAZOLE AND PHENYTOIN IN EPILEPTIC PATIENTS [J].
ANDERSSON, T ;
LAGERSTROM, PO ;
UNGE, P .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :329-333
[2]   EFFECT OF OMEPRAZOLE AND CIMETIDINE ON PLASMA DIAZEPAM LEVELS [J].
ANDERSSON, T ;
ANDREN, K ;
CEDERBERG, C ;
EDVARDSSON, G ;
HEGGELUND, A ;
LUNDBORG, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (01) :51-54
[3]   SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS [J].
ANDERSSON, T ;
REGARDH, CG ;
DAHLPUUSTINEN, ML ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :415-416
[4]   LACK OF EFFECT OF OMEPRAZOLE TREATMENT ON STEADY-STATE PLASMA-LEVELS OF METOPROLOL [J].
ANDERSSON, T ;
LUNDBORG, P ;
REGARDH, CG .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (01) :61-65
[5]  
BANNISTER J, 1990, AUG WORLD C GASTR SY
[6]   A COMPARISON OF 2 DIFFERENT DOSES OF OMEPRAZOLE VERSUS RANITIDINE IN TREATMENT OF DUODENAL-ULCERS [J].
BARDHAN, KD ;
PORRO, GB ;
BOSE, K ;
DALY, M ;
HINCHLIFFE, RFC ;
JONSSON, E ;
LAZZARONI, M ;
NAESDAL, J ;
RIKNER, L ;
WALAN, A .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1986, 8 (04) :408-413
[7]   IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].
BERTILSSON, L ;
HENTHORN, TK ;
SANZ, E ;
TYBRING, G ;
SAWE, J ;
VILLEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355
[8]   CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547
[9]   HUMAN CYTOCHROME P-450PA (P-450IA2), THE PHENACETIN O-DEETHYLASE, IS PRIMARILY RESPONSIBLE FOR THE HEPATIC 3-DEMETHYLATION OF CAFFEINE AND N-OXIDATION OF CARCINOGENIC ARYLAMINES - (AROMATIC-AMINES HETEROCYCLIC AMINES CARCINOGEN METABOLISM) [J].
BUTLER, MA ;
IWASAKI, M ;
GUENGERICH, FP ;
KADLUBAR, FF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) :7696-7700
[10]   A URINARY METABOLITE RATIO THAT REFLECTS SYSTEMIC CAFFEINE CLEARANCE [J].
CAMPBELL, ME ;
SPIELBERG, SP ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (02) :157-165